Consumers and their doctors all know about LDL and the need to lower the so-called bad cholesterol. But what about the treatments beyond those that lower LDL? James Stolzenbach, who oversees clinical research in the area of dyslipidemia and renal drug development at Abbott Laboratories, tells host Bruce Japsen about new developments in treating and managing cholesterol beyond lowering LDL.
Facebook Comments